Linifanib - Small Molecule (ID:10182-101)

HMS LINCS ID: 10182-101
Name: Linifanib
Alternative Names: ABT-869; AL-39324
LINCS ID: LSM-1183
PubChem CID: 11485656
ChEBI ID:
ChEMBL ID:
Molecular Mass: 375.15
InChi: InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
InChi Key: MPVGZUGXCQEXTM-UHFFFAOYSA-N
SMILES: CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
Relevant Citations:
Comments:
Date Publicly Available:
Most Recent Update: 2016-04-04

Target Affinity:

(see Study 20000)
Target Affinity Spectrum Value HUGO Gene Name
1
(Kd <100 nM)
AURKC, CDK13, CDK19, CDK8, CSF1R, DDR1, EPHB6, FLT1, FLT3, FLT4, HIPK4, KDR, KIT, MUSK, PDGFRA, PDGFRB
2
(equivalent to 100 nM ≤ Kd < 1µM)
AIM1, AURKB, AXL, BMPR1B, EPHA6, EPHA7, EPHB1, FRK, LTK, MAP3K19, MAP4K1, MAP4K5, MAPK11, MAPK9, MERTK, MKNK2, NTRK3, RET, ROCK2, SLK, STK10, STK32A, STK32B, TAOK1, TAOK3, TEK, TIE1
3
(equivalent to 1µM ≤ Kd < 10 µM)
ABL1, ALK, AURKA, BMPR2, C8orf44-SGK3, CDC42BPG, CDC7, CDK1, CDK11A, CDK11B, CDK16, CDK7, CDK9, CHUK, CLK1, CLK4, CSNK1A1, DDR2, DYRK1A, DYRK3, DYRK4, EEF2K, EGFR, EPHA3, EPHA5, EPHB2, EPHB3, EPHB4, ERBB4, GAK, GRK5, HIPK2, HIPK3, IKBKB, INSRR, IRAK1, IRAK4, LATS1, LATS2, LIMK2, MAP2K5, MAP4K2, MAP4K3, MAPK10, MAPK12, MAPK13, MAPK15, MATK, MET, MINK1, MKNK1, MST1, MST1R, MYLK2, MYO3B, NEK4, NTRK1, NTRK2, PBK, PLK3, PLK4, PRKACA, PRKCG, PRKCI, PRKCZ, RIPK1, ROCK1, RPS6KA4, RPS6KA5, RPS6KB1, SGK2, SGK3, STK26, STK3, STK33, STK4, TBK1, TKT, TNIK, TSSK2
10
(confirmed non-binding)
(Click to show)

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20000
Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library.
Analysis
20237
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1.
 Microscopy/Imaging
20238
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2.
 Microscopy/Imaging
20239
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3.
 Microscopy/Imaging
20240
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1.
 Microscopy/Imaging
20241
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2.
 Microscopy/Imaging
20242
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3.
 Microscopy/Imaging
20243
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 7 of 15: Mean cell count and mean growth rate across all replicates.
 Microscopy/Imaging
20245
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1.
 Microscopy/Imaging
20246
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2.
 Microscopy/Imaging
20247
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3.
 Microscopy/Imaging
20248
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1.
 Microscopy/Imaging
20249
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2.
 Microscopy/Imaging
20250
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3.
 Microscopy/Imaging
20251
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates.
 Microscopy/Imaging
20252
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics.
 Analysis

Batch Information:

HMS LINCS Batch ID Provider Provider Batch ID
10182-101-1 Haoyuan chemexpress HY-50751_1-20110708